TY - JOUR
T1 - Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers
T2 - results of an international, randomized, open-label study
AU - Camus, Daniel
AU - Djossou, Felix
AU - Schilthuis, Herbert J
AU - Høgh, Birthe
AU - Dutoit, Emmanuel
AU - Malvy, Denis
AU - Roskell, Neil S
AU - Hedgley, Corinne
AU - De Boever, Erika H
AU - Miller, Gerri B
AU - International Malarone Study Team
PY - 2004/6/15
Y1 - 2004/6/15
N2 - Atovaquone-proguanil has been shown to be effective and well tolerated for malaria prophylaxis in residents of countries of endemicity and in nonimmune adult travelers, but data about traveling children are limited. In a randomized, open-label, multicenter prophylaxis trial, 221 nonimmune pediatric travelers (age, 2-17 years) received either atovaquone-proguanil or chloroquine-proguanil. Safety and clinical outcome were evaluated 7, 28, and 60 days after travel. By posttravel day 7, a total of 39 (35%) of 110 atovaquone-proguanil and 41 (37%) of 111 chloroquine-proguanil recipients reported > or =1 adverse event. The data indicate that, over the course of treatment, fewer atovaquone-proguanil recipients had treatment-related adverse events (8% vs. 14%), including gastrointestinal complaints (5% vs. 10%). Two subjects discontinued prophylaxis because of drug-related adverse events; both had received chloroquine-proguanil. Observed compliance with prophylaxis was similar before and during travel, but it was higher for atovaquone-proguanil in the posttravel period. No study participant developed malaria. Atovaquone-proguanil was well tolerated and is an important addition to the limited arsenal of prophylactic agents available to children.
AB - Atovaquone-proguanil has been shown to be effective and well tolerated for malaria prophylaxis in residents of countries of endemicity and in nonimmune adult travelers, but data about traveling children are limited. In a randomized, open-label, multicenter prophylaxis trial, 221 nonimmune pediatric travelers (age, 2-17 years) received either atovaquone-proguanil or chloroquine-proguanil. Safety and clinical outcome were evaluated 7, 28, and 60 days after travel. By posttravel day 7, a total of 39 (35%) of 110 atovaquone-proguanil and 41 (37%) of 111 chloroquine-proguanil recipients reported > or =1 adverse event. The data indicate that, over the course of treatment, fewer atovaquone-proguanil recipients had treatment-related adverse events (8% vs. 14%), including gastrointestinal complaints (5% vs. 10%). Two subjects discontinued prophylaxis because of drug-related adverse events; both had received chloroquine-proguanil. Observed compliance with prophylaxis was similar before and during travel, but it was higher for atovaquone-proguanil in the posttravel period. No study participant developed malaria. Atovaquone-proguanil was well tolerated and is an important addition to the limited arsenal of prophylactic agents available to children.
KW - Adolescent
KW - Antimalarials/administration & dosage
KW - Atovaquone
KW - Child
KW - Child, Preschool
KW - Chloroquine/administration & dosage
KW - Drug Therapy, Combination
KW - Humans
KW - Infant
KW - Malaria/prevention & control
KW - Naphthoquinones/administration & dosage
KW - Patient Compliance
KW - Proguanil/administration & dosage
KW - Travel
U2 - 10.1086/421086
DO - 10.1086/421086
M3 - Journal article
C2 - 15227617
SN - 1058-4838
VL - 38
SP - 1716
EP - 1723
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 12
ER -
